Although the International Prognostic Index (IPI) score is a valuable prognostic tool in diffuse large B-cell lymphoma (DLBCL), other risk-stratifying factors may be of value. The aim of this study was to define the prognostic value of EBV expression in de novo nodal DLBCL. Seventy-four cases were selected between January 2002 and December 2007. Clinical data were reviewed and tissue samples were evaluated for expression of CD20, CD10, bcl-6, MUM1, and EBV-encoded RNA (EBER). Of 74 evaluated cases, 53 cases (72%) were of non-germinal center-like subtype and 11 cases (15%) were positive for EBER. In a univariate analysis of the 57 patients who received chemotherapy, factors associated with survival were EBV status, performance status, LDH level, and IPI score. Using a multivariate analysis, a prognostic model was developed using IPI score and EBV status, which showed statistical significance. Our study supports EBV status as a powerful prognostic factor in de novo nodal DLBCL. Prospective studies should be carried to validate this hypothesis. © 2010 Informa Healthcare USA, Inc.
Morales, D., Beltran, B., De Mendoza, F. H., Riva, L., Yabar, A., Quiñones, P., Butera, J. N., & Castillo, J. (2010). Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leukemia and Lymphoma, 66-72. https://doi.org/10.3109/10428190903308015